The Life Ledger

Fitness is a way of life.

(No Ratings Yet)

 Loading ...

Fetched from Food and Drug Administration Press Releases

The U.S. Food and Drug Administration today announced its intention to take enforcement action against companies marketing unapproved injectable colchicine, a drug used to treat gout. Colchicine is a highly toxic drug that can easily be administered in excessive doses, especially when given intravenously. There is a narrow margin between an effective dose of the drug and a toxic dose that can result in serious health risks, including death. The FDA is aware of 50 reports of adverse events associated with the use of intravenous colchicine, including 23 deaths. Potentially fatal effects include low blood cell counts, cardiac events, and organ failure.

Read more here: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01791.html

Thank you for visiting The Life Ledger. If you enjoyed this article, check out the related posts below and subscribe to our feed.

Related posts:

1. FDA’s Strategic Plan: Charting Our Course for the Future [Fetched Feed]
2. FDA Announces Permanent Injunction against Food Companies, Executives [Fetched Feed]